Beacon proudly introduces highly potent multi-targeted third generation BCR-ABL Tyrosine Kinase Inhibitor Ponatinib which is the only treatment indicated for the adult patients with T315I+ CML or T315I+ Ph+ ALL or where no other TKI is indicated.
We are pleased to inform you that Team BML is going to launch Ponatinix Tablet for global market. It will be available in two strengths (45 mg and 15 mg).
Each pack of Ponatinix 45 will contains 30 tablets and Ponatinix 15 will contains 60 tablets in HDPE pot. The product is only for global patients.
Ponatinib is a prescription medication which is a kinase inhibitor indicated for:
- Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.
- Treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).